标题
New Developments in the Treatment of Schizophrenia: An Expert Roundtable
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 26, Issue 5, Pages 322-330
出版商
Oxford University Press (OUP)
发表日期
2023-03-18
DOI
10.1093/ijnp/pyad011
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Dose dependent augmentation of neuroplasticity-based auditory learning in schizophrenia: a double-blind, placebo-controlled, randomized, target engagement clinical trial of the N-methyl-D-aspartate-type glutamate receptor (NMDAR) agonist d-serine
- (2023) Pejman Sehatpour et al. BIOLOGICAL PSYCHIATRY
- The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
- (2023) Christoph U. Correll et al. World Psychiatry
- Markers of muscarinic deficit for individualized treatment in schizophrenia
- (2023) Heiner Stuke Frontiers in Psychiatry
- Determination of D-serine and D-alanine Tissue Levels in the Prefrontal Cortex and Hippocampus of Rats After a Single Dose of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, with Potential Antipsychotic and Antidepressant Properties
- (2023) Chih-Chia Huang et al. NEUROCHEMICAL RESEARCH
- The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease
- (2022) Daniel C. Javitt et al. SCHIZOPHRENIA RESEARCH
- Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
- (2022) Michael Davidson et al. SCHIZOPHRENIA BULLETIN
- Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
- (2022) Christoph U. Correll et al. World Psychiatry
- Clozapine’s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia
- (2022) Andrea de Bartolomeis et al. PHARMACOLOGY & THERAPEUTICS
- Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia
- (2022) Mikkel Højlund et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial
- (2022) John H Krystal et al. LANCET
- Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
- (2021) Stephen K. Brannan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Schizophrenia outcomes in the 21st century: A systematic review
- (2021) Peter Huxley et al. Brain and Behavior
- How do we address treating the negative symptoms of schizophrenia pharmacologically?
- (2021) Joshua T. Kantrowitz EXPERT OPINION ON PHARMACOTHERAPY
- D-Serine: A Cross Species Review of Safety
- (2021) Amir Meftah et al. Frontiers in Psychiatry
- Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions
- (2021) Joshua T. Kantrowitz CNS DRUGS
- P.0794 KarXT treatment improves cognitive performance in cognitively impaired patients with schizophrenia: a post-hoc analysis of the phase 2 EMERGENT-1 study
- (2021) C. Sauder et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
- (2021) Nina Dedic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Prospective, observational, single-centre cohort study with an independent control group matched for age and sex aimed at investigating the significance of cholinergic activity in patients with schizophrenia: study protocol of the CLASH-study
- (2021) Benedikt Schick et al. BMJ Open
- Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia
- (2021) Ju-Chun Pei et al. Frontiers in Psychiatry
- Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
- (2021) Christoph U. Correll et al. npj Schizophrenia
- TAAR1 and Psychostimulant Addiction
- (2020) Jianfeng Liu et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
- Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers
- (2020) Joshua T. Kantrowitz et al. NEUROPSYCHOPHARMACOLOGY
- A Non–D2-Receptor-Binding Drug for the Treatment of Schizophrenia
- (2020) Kenneth S. Koblan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
- (2020) Olga B. Baltzersen et al. Frontiers in Pharmacology
- Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
- (2020) Joshua T. Kantrowitz CNS DRUGS
- Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia
- (2020) Brian Dean et al. PSYCHIATRY RESEARCH
- The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain
- (2020) Caterina Montani et al. NEUROPSYCHOPHARMACOLOGY
- SEP-363856, A NOVEL PSYCHOTROPIC AGENT WITH A UNIQUE, NON-D2 RECEPTOR MECHANISM OF ACTION
- (2019) Nina Dedic et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis
- (2019) Maximilian Huhn et al. LANCET
- Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
- (2019) Stephen J. Kaar et al. NEUROPHARMACOLOGY
- New discoveries for an old drug: a review of recent olanzapine research
- (2019) Amir M Meftah et al. POSTGRADUATE MEDICINE
- N -methyl- d -aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia
- (2018) Joshua T. Kantrowitz SCHIZOPHRENIA RESEARCH
- Neurophysiological Effects of Bitopertin in Schizophrenia
- (2017) Joshua T. Kantrowitz et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges
- (2017) Mark D. Berry et al. PHARMACOLOGY & THERAPEUTICS
- Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
- (2017) Marco Solmi et al. Therapeutics and Clinical Risk Management
- Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2017) Chieh-Hsin Lin et al. BIOLOGICAL PSYCHIATRY
- A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
- (2014) AnnCatherine M Downing et al. BMC Psychiatry
- Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: Role of D2 dopamine autoreceptors
- (2014) D. Leo et al. NEUROPHARMACOLOGY
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions
- (2014) Petter Andreas Ringen et al. Frontiers in Psychiatry
- D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy
- (2013) Silvia Sacchi et al. CURRENT PHARMACEUTICAL DESIGN
- Add-on Treatment of Benzoate for Schizophrenia
- (2013) Hsien-Yuan Lane et al. JAMA Psychiatry
- A Systematic Review and Meta-Analysis of Recovery in Schizophrenia
- (2012) E. Jaaskelainen et al. SCHIZOPHRENIA BULLETIN
- Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor
- (2011) S. Espinoza et al. MOLECULAR PHARMACOLOGY
- Striatal Muscarinic Receptors Promote Activity Dependence of Dopamine Transmission via Distinct Receptor Subtypes on Cholinergic Interneurons in Ventral versus Dorsal Striatum
- (2010) S. Threlfell et al. JOURNAL OF NEUROSCIENCE
- Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
- (2008) Anantha Shekhar et al. AMERICAN JOURNAL OF PSYCHIATRY
- What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
- (2008) A. S. Kemp et al. SCHIZOPHRENIA BULLETIN
- Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia
- (2008) Caroline Madeira et al. SCHIZOPHRENIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now